Mankind Pharma Ltd.

1424.15 -41.90 ▼-2.9%

05 June 2023, 04:01:00 PM
Volume: 51,449

Company Profile

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.mankindpharma.com
Market Cap 57,049.80 Cr.
Enterprise Value(EV) 57,511.89 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 35.78 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 39.80 Trailing Twelve Months Ending 2022-03
Industry PE 33.51 Trailing Twelve Months Ending 2022-03
Book Value / Share 261.55 Trailing Twelve Months Ending 2022-03
Price to Book Value 5.44 Calculated using Price: 1,424.15
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 40.06 Cr. 400,588,440 Shares
FaceValue 1

Mankind Pharma Ltd. Delivery

Delivered Qty
Traded Qty

Mankind Pharma Ltd. Performance

1 Day
-2.86%
1 Week
+4.13%
1 Month
3 Month
6 Month
1 Year
2 Year
5 Year
10 Year

Mankind Pharma Ltd. Fundamental Ratios

8 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 21.61 25.06 24.28 23.69 21.06 33.12 31.51 26.72
Return on Capital Employed (%) 30.32 36.47 35.49 33.47 28.49 43.22 39.97 33.96
Return on Assets (%) 17.54 20.08 19.10 16.98 14.22 22.94 22.79 18.83

Mankind Pharma Ltd. Balance Sheet

Particulars 8 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Shh. Funds 2,055 2,257 2,927 2,881 2,823 3,485 4,722 6,155
Non Curr. Liab. 28 34 53 49 78 103 107 169
Curr. Liab. 433 528 663 1,296 1,024 1,251 1,353 2,623
Minority Int. 16 29 98 134 159 186 141 161
Equity & Liab. 2,532 2,848 3,741 4,360 4,084 5,025 6,324 9,108
Non Curr. Assets 859 1,142 1,672 1,787 2,085 2,206 2,417 4,702
Curr. Assets 1,673 1,707 2,069 2,574 1,998 2,820 3,907 4,407
Misc. Exp. not W/O
Total Assets 2,532 2,848 3,741 4,360 4,084 5,025 6,324 9,108

Mankind Pharma Ltd. Profit and Loss

Particulars 8 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Net Sales 3,323 3,944 4,382 4,949 4,980 5,872 6,214 7,782
Other Income 76 71 108 72 53 104 171 196
Total Income 3,399 4,015 4,490 5,021 5,033 5,976 6,385 7,978
Total Expenditure -2,738 -3,185 -3,536 -3,933 -4,055 -4,427 -4,565 -5,791
PBIDT 662 830 953 1,088 978 1,549 1,820 2,187
Interest -2 -3 -4 -25 -44 -23 -21 -60
Depreciation -39 -43 -31 -46 -69 -99 -119 -167
Taxation -177 -244 -290 -329 -264 -382 -399 -522
Exceptional Items
PAT 444 540 629 688 601 1,045 1,293 1,453
Minority Interest -6 -28 -32 -26 -28 -19
Share Associate 1 2 0 -3 10 12
Other Related Items
Consolidated Net Profit 439 542 629 656 579 1,030 1,265 1,433
Adjusted EPS 11 14 16 16 14 26 32 36

Mankind Pharma Ltd. Cash Flow

Particulars 8 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 280 537 628 639 600 1,072 1,137 920
Cash Fr. Inv. -348 -152 -625 -505 -444 -439 -1,222 -1,369
Cash Fr. Finan. 9 -361 2 -89 -175 -527 -8 605
Net Change -59 25 5 46 -19 106 -93 155
Cash & Cash Eqvt 39 78 87 135 116 226 127 283

Mankind Pharma Ltd. Shareholding Pattern

1 Qtrs 2023-03 (%)
Promoter 76.50
Public 23.50
Depository Receipts 0.00
Promoter Holding Pledge (%) 0.00

Mankind Pharma Ltd. Announcements

Wed, 31 May 2023
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015
In pursuant to the provisions of Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations 2015 (PIT Regulations) please find enclosed herewith a copy of Code of Practice and Procedure for Fair Disclosure of Unpublished Price Sensitive Information (Fair Disclosure Code). The copy of the Fair Disclosure Code is also available on the website of the Company.
Wed, 31 May 2023
Authorised Key Managerial Personnel To Determine Materiality Of An Event Or Information And Its Disclosure
Pursuant to Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 please note that the following Key Managerial Personnel of the Company are severally authorised for the purpose of determining the materiality of an event or information to the Stock Exchange(s):1. Mr. Rajeev Juneja - Vice Chairman & Managing Director 2. Mr. Sheetal Arora - Chief Executive Officer 3. Mr. Arjun Juneja - Chief Operating Officer 4. Mr. Ashutosh Dhawan - Chief Financial Officer The following Key Managerial Personnel of the Company are severally authorised for the purpose of dissemination of material event/information to the Stock Exchange 1. Mr. Ashutosh Dhawan - Chief Financial Officer 2. Mr. Pradeep Chugh - Company Secretary & Compliance Officer
Wed, 31 May 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith extracts of the consolidated audited financial results for the quarter and financial year ended 31st March 2023 as published in "Business Standard" Financial Express and "Jansatta" on 31st May 2023.

Mankind Pharma Ltd. Technical Scans

Mon, 05 Jun 2023
Close Within 52 Week High Zone Close Within 52 Week High Zone
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
Close Entering 52 Week Low Zone Close Entering 52 Week Low Zone
William %R Bearish William %R Bearish
Bearish Harami Bearish Harami

Mankind Pharma Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 242,260.85 1,009.70 +1.0%
Divi's Laboratories Ltd. 91,882.66 3,461.15 -1.6%
Cipla Ltd. 78,680.17 974.70 +1.0%
Dr. Reddy's Laboratories Ltd. 76,651.29 4,611.30 +0.0%
Apollo Hospitals Enterprise Ltd. 71,154.71 4,948.70 -0.4%
Torrent Pharmaceuticals Ltd. 60,075.76 1,770.00 -0.4%
Zydus Lifesciences Ltd. 51,592.04 510.30 -1.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 28.59 1,009.70 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-03 50.39 3,461.15 -1.6%
Cipla Ltd. Consolidated 2023-03 28.08 974.70 +1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 17.04 4,611.30 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 86.87 4,948.70 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 48.12 1,770.00 -0.4%
Zydus Lifesciences Ltd. Consolidated 2023-03 26.35 510.30 -1.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 4.33 1,009.70 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-03 7.20 3,461.15 -1.6%
Cipla Ltd. Consolidated 2023-03 3.36 974.70 +1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 3.30 4,611.30 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 11.50 4,948.70 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9.66 1,770.00 -0.4%
Zydus Lifesciences Ltd. Consolidated 2023-03 2.95 510.30 -1.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,009.70 +1.0%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,461.15 -1.6%
Cipla Ltd. Consolidated 2022-03 0.04 974.70 +1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,611.30 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,948.70 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,770.00 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 510.30 -1.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,009.70 +1.0%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,461.15 -1.6%
Cipla Ltd. Consolidated 2022-03 13.10 974.70 +1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,611.30 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,948.70 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,770.00 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 510.30 -1.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,009.70 +1.0%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,461.15 -1.6%
Cipla Ltd. Consolidated 2022-03 13.10 974.70 +1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,611.30 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,948.70 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,770.00 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 510.30 -1.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,009.70 +1.0%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,461.15 -1.6%
Cipla Ltd. Consolidated 2022-03 21,763.34 974.70 +1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,611.30 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,948.70 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,770.00 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 510.30 -1.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,009.70 +1.0%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,461.15 -1.6%
Cipla Ltd. Consolidated 2022-03 2,559.47 974.70 +1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,611.30 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,948.70 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,770.00 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 510.30 -1.6%

Mankind Pharma Ltd. FAQ's

What is Mankind Pharma share price?

Can I buy Mankind Pharma shares now?

What is the Market Cap of Mankind Pharma?

What are the key metrics to analyse Mankind Pharma?

What is the 52 Week High and Low of Mankind Pharma?

What is the trend of Mankind Pharma share price?